Heartflow, Inc.
HTFL- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001464521
In the last 90 days, Heartflow, Inc. insiders filed 0 open-market purchases and 14 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $2.19B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:13 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $116.8M (66.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Mar 18, 2026 |
| Revenue | $176.0M |
| Cost of revenue | $40.8M |
| Gross profit | $135.2M |
| Operating expenses | $199.3M |
| Research and development | $64.9M |
| Selling, general and administrative | $134.3M |
| Operating income | -$64.1M |
| Income tax | -$76.0K |
| Net income | -$116.8M |
| EPS, basic | $-3.17 |
| EPS, diluted | $-3.17 |
| Weighted shares, basic | 36.9M |
| Weighted shares, diluted | 36.9M |
| Margins and growth | |
| Gross margin | 76.8% |
| Operating margin | -36.4% |
| Net margin | -66.3% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Mar 18, 2026 |
| Cash and equivalents | $44.8M |
| Short-term investments | $132.0M |
| Accounts receivable | $29.3M |
| Total current assets | $220.2M |
| Property, plant and equipment | $8.59M |
| Total assets | $359.5M |
| Accounts payable | $3.17M |
| Total current liabilities | $42.4M |
| Total liabilities | $58.8M |
| Shareholders' equity | $300.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 |
|---|---|
| Period end | Dec 31, 2025 |
| Filing | 10-K |
| Reported | Mar 18, 2026 |
| Operating cash flow | -$54.0M |
| Capital expenditures | $5.03M |
| Free cash flow | -$59.0M |
| Depreciation and amortization | $5.44M |
| Stock-based compensation | $14.0M |
| Investing cash flow | -$238.6M |
| Financing cash flow | $286.0M |
| Net change in cash | -$6.36M |
| Ratio | |
| Stock-based compensation, % of revenue | 7.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.